ZBIO
Zenas BioPharma, Inc. Common Stock
NASDAQ: ZBIO · HEALTHCARE · BIOTECHNOLOGY
$17.55
-2.55% today
Updated 2026-04-29
Market cap
$1.09B
P/E ratio
—
P/S ratio
109.46x
EPS (TTM)
$-8.44
Dividend yield
—
52W range
$9 – $45
Volume
0.7M
WallStSmart proprietary scores
23
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D7.0
Quality
B+2.5
Profitability
F5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
0.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$42.00
+139.32%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy7 Buy1 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Debt/equity 0.00x — low leverage
Risks
- Altman Z 0.90 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-82.41M
- Revenue declining -100.00% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $50.00M | $5.00M | $10.00M | $10.00M |
| Net income | $-119.28M | $-37.12M | $-156.99M | $-377.74M | $-240.44M |
| EPS | — | — | — | — | $-8.44 |
| Free cash flow | $-67.85M | $-30.55M | $-119.81M | $-172.35M | $-82.41M |
| Profit margin | — | -74.25% | -3,139.76% | -3,777.37% | — |
Peer comparison
Smart narrative
Zenas BioPharma, Inc. Common Stock trades at $17.55. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 0.90, it sits in the distress. TTM revenue stands at $10.00M.
Frequently asked questions
What is Zenas BioPharma, Inc. Common Stock's stock price?
Zenas BioPharma, Inc. Common Stock (ZBIO) trades at $17.55.
Is Zenas BioPharma, Inc. Common Stock overvalued?
Smart Value Score 23/100 (Grade F, Strong Sell).
What is the price target of Zenas BioPharma, Inc. Common Stock (ZBIO)?
The analyst target price is $42.00, representing +139.3% upside from the current price of $17.55.
What is Zenas BioPharma, Inc. Common Stock's revenue?
TTM revenue is $10.00M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
0.90 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio109.46x
ROE-136.20%
Beta—
50D MA$22.59
200D MA$24.14
Shares out0.06B
Float0.04B
Short ratio—
Avg volume0.7M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—